{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:14:47Z","timestamp":1790648087041,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s40265-018-0907-5","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T08:57:14Z","timestamp":1524128234000},"page":"781-785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Ibalizumab: First Global Approval"],"prefix":"10.1007","volume":"78","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"907_CR1","unstructured":"US FDA. FDA approves new HIV treatment for patients who have limited treatment options [media release]. 6 Mar 2018. \n                    https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm599657.htm\n                    \n                  ."},{"key":"907_CR2","unstructured":"US FDA. TROGARZO\u2122 (ibalizumab-uiyk): US prescribing Information. 2018. \n                    www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761065lbl.pdf\n                    \n                  . Accessed 21 Mar 2018."},{"key":"907_CR3","unstructured":"Genentech Inc. Genentech announces expiration of Hart-Scott-Rodino waiting period and completes acquisition of Tanox [media release]. 3 Aug 2007. \n                    http:\/\/www.gene.com\n                    \n                  ."},{"key":"907_CR4","unstructured":"TaiMed Biologics. WuXi PharmaTech to manufacture ibalizumab for TaiMed Biologics [media release]. 28 Aug 2012. \n                    http:\/\/www.taimedbiologics.com\n                    \n                  ."},{"key":"907_CR5","unstructured":"Theratechnologies, TaiMed Biologics. Theratechnologies and TaiMed Biologics sign exclusive marketing and distribution agreement for ibalizumab [media release]. 18 Mar 2016. \n                    http:\/\/www.theratech.com\n                    \n                  ."},{"key":"907_CR6","unstructured":"US FDA. Orphan Drug Designations and Approvals. \n                    https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=321910\n                    \n                  . Accessed 10 Apr 2018."},{"issue":"1","key":"907_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0b013e3182732746","volume":"62","author":"CS Pace","year":"2013","unstructured":"Pace CS, Fordyce MW, Franco D, et al. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr. 2013;62(1):1\u20139.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"12","key":"907_CR8","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.str.2010.09.017","volume":"18","author":"MM Freeman","year":"2010","unstructured":"Freeman MM, Seaman MS, Rits-Volloch S, et al. Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure.\u00a02010;18(12):1632\u201341.","journal-title":"Structure."},{"key":"907_CR9","unstructured":"Weinheimer S, Cohen Z, Marsolais C, et al. Ibalizumab susceptibility in patient HIV isolates resistant to antiretrovirals [abstract no. 561]. In: 25th Conference on Retroviruses and Opportunistic Infections. 2018."},{"issue":"8","key":"907_CR10","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1128\/JVI.02237-10","volume":"85","author":"J Toma","year":"2011","unstructured":"Toma J, Weinheimer SP, Stawiski E, et al. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol. 2011;85(8):3872\u201380.","journal-title":"J Virol."},{"issue":"2","key":"907_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/AAC.00942-08","volume":"53","author":"JM Jacobson","year":"2009","unstructured":"Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009;53(2):450\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl. 1","key":"907_CR12","first-page":"S1","volume":"3","author":"J Lalezari","year":"2016","unstructured":"Lalezari J, Fessel WJ, Schrader S, et al. Primary efficacy endpoint and safety results of ibalizumab in a phase 3 study of heavily treatment-experienced patients with multidrug-resistant human immunodeficiency virus-1 infection [abstract no. LB-6 plus oral presentation]. Open Forum. Infectious Diseases. 2016;3(Suppl. 1):S1.","journal-title":"Infectious Diseases."},{"key":"907_CR13","unstructured":"Lewis S, Fessel J, Emu B, et al. Long-acting ibalizumab in patients with multi-drug resistant HIV-1: a 24-week study [abstract no. 438 plus poster 449LB]. In: 24th conference on retroviruses and opportunistic infections. 2017."},{"issue":"Suppl. 1","key":"907_CR14","first-page":"S38","volume":"4","author":"B Emu","year":"2017","unstructured":"Emu B, Fessel WJ, Schrader S, et al. Forty-eight-week safety and efficacy on-treatment analysis of ibalizumab in patients with multi-drug resistant HIV-1 [abstract no. 1686 plus oral presentation]. Open Forum. Infect Dis. 2017;4(Suppl. 1):S38\u20139.","journal-title":"Infect Dis."},{"key":"907_CR15","unstructured":"Khanlou H, Gathe JJ, Schrader S, et al. Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patients: a phase 2b study [abstract no. H2-794b plus oral presentation]. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. 2011."}],"updated-by":[{"DOI":"10.1007\/s40265-018-0926-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0907-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0907-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0907-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:19:34Z","timestamp":1555633174000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0907-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0907-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-018-0926-2","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,19]]},"assertion":[{"value":"19 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Ibalizumab: First Global Approval, written by Anthony Markham, was originally published Online First without open access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}